MediWound Ltd. (MDWD) Q1 2025 Earnings – Full Coverage скачать в хорошем качестве

MediWound Ltd. (MDWD) Q1 2025 Earnings – Full Coverage

*MediWound Ltd. (MDWD) Q1 2025 Earnings – Full Coverage* *Key Highlights:* *Financials* – Q1 revenue $4,000K, down from $5,000K YoY; net loss $700K; cash $38,700K; $500B global wound care market. *Operations* – EscharEx Phase III on track; NexoBrid U.S. sales up 207%; Keresys collaboration added; tariffs impact ~1% via mitigation. *Strategy* – CEO Ofer Gonen emphasized EscharEx; CFO Hani Luxenberg highlighted cash position; focus on manufacturing scale-up; tariffs mitigated via U.S. operations. *Outlook* – 2025 revenue $24,000K; 2026 revenue $30,000K-$33,000K; EscharEx interim data mid-2026; new facility operational 2026. *Timestamps:* [00:00] – Opening Remarks and Introduction [02:28] – CEO Update: Q1 Results (Ofer Gonen) [07:47] – CEO Update: EscharEx Progress [09:40] – CEO Update: NexoBrid Growth [12:00] – CFO Update: Financial Results (Hani Luxenberg) [16:14] – Q&A Session Begins [16:14] – Q&A: Manufacturing, Enrollment (Chase Knickerbocker, Craig Hallum) [20:45] – Q&A: Stockpiling, EscharEx Trial (RK, H.C. Wainwright) [26:44] – Q&A: Pricing Strategy, U.S. Capacity (Michael Okunewicz, Maxim Group) [31:10] – Q&A: BARDA Funding, Financials (Scott Henry, Alliance Global Partners) *Keywords:* MediWound, Q1 2025 earnings, MDWD, EscharEx, NexoBrid, wound care, enzymatic debridement *Buy, Hold, or Sell?* MediWound Ltd. (MDWD) is a BUY. Q1 revenue down to $4,000K but EscharEx Phase III progress and NexoBrid sales up 207% in a $500B global wound care market signal strong potential; tariff impact, ~1%, is minimal due to U.S.-centric operations. *Max Position* – Allocate 2-3% in a diversified portfolio. *Comment below with your thoughts! Subscribe for more updates!* *Full Details:* [MediWound Investor Relations](https://www.mediwound.com/investors/) *Disclaimer:* This video includes segments from the earnings call by MediWound Ltd., used solely for educational and informational purposes under fair use (Section 107, US Copyright Act). No affiliation or endorsement by MediWound is implied. All rights to the original content remain with the company. For the official call, visit [https://www.mediwound.com/investors/](https://www.mediwound.com/investors/). For inquiries or requests for removal, please contact us at [email protected].